Podcast thumbnail for Don't Just Read the Abstract

Don't Just Read the Abstract

Claim This Podcast

by Richard Buka

5.0(8 reviews)
35 episodes
Updated Bi-weekly
Accepts GuestsHas SponsorsLocation 🇬🇧
25

Podcast Authority

Beta
PoorBased on show quality, social media presence, reviews, charts, and more
Pod Engine
Quality37
Social0
YouTube0
Engagement32

Podcast Overview

<p>Want to stay up-to-date on the very latest developments in non-malignant haematology? Don't have the time or skills to critically appraise important papers? Join Pip and Rich, two haematology doctors on a journey of learning and discovery. Each episode, they will discuss a seminal trial, critically appraise the paper, interview a study author, and discuss the implications of the trial on clinical practice with a subject expert. CPD credits are available from RCPath. The podcast is sponsored by Sobi as a hands-off educational grant. Sobi have no editorial input whatsoever.</p><br><p>This podcast helps you to go beyond the abstract, delving deep into the methods, results, subanalyses, and implications. Interviews with authors gives a real-life perspective on the running of a clinical trial allowing explanations of why they did what they did and good honest discussion on limitations and how they might do it differently next time.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>

Language

🇺🇲

Publishing Since

1/21/2024

Unlock The Full Podcast Authority Score Report

See how your podcast performs across key metrics

25

Podcast Authority

Beta
PoorBased on show quality, social media presence, reviews, charts, and more
Pod Engine
Quality37
Social0
YouTube0
Engagement32
5
Excellent Areas
3
Good Performance
11
Growth Opportunities
excellent
Episode Length
55 minutes
Performing excellently!
good
Show Notes Quality
3.0/5

Recommendations available

Unlock the full report to see detailed tips

needs improvement
Publishing Consistency
Every 27 days

Recommendations available

Unlock the full report to see detailed tips

+16 More Metrics

Unlock comprehensive insights including:

  • • YouTube presence analysis
  • • Social media reach metrics
  • • RSS compliance scoring
  • • Podcast 2.0 features
  • • Technical standards
What's Included in Your Full Report

Detailed Analytics

  • Complete breakdown of all 19 authority metrics
  • Personalized recommendations for each metric
  • Industry benchmarks and comparisons
  • Technical RSS feed analysis and compliance scoring

Growth Strategies

  • Step-by-step action plans for improvement
  • Quick wins to boost your score immediately
  • Pro tips from successful podcasters
Get your free podcast insights report

See how your show performs across every key metric

Instant delivery
No spam
Attract Better Guests

High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.

Secure Sponsorships

Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.

Grow Your Audience

Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.

1 verified contact email on file for Don't Just Read the Abstract

Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.

Recent Episodes

Episode thumbnail for Is emicizumab finished? The FRONTIER2 trial of the novel bispecific antibody, denecimig (Mim8) for haemophilia A

June 23, 2026

Is emicizumab finished? The FRONTIER2 trial of the novel bispecific antibody, denecimig (Mim8) for haemophilia A

On this episode, Pip and Rich discuss the <a href="https://www.nejm.org/doi/10.1056/NEJMoa2517384" rel="noopener noreferrer" target="_blank">FRONTIER2</a>, the phase 3 trial of Mim8 (denecimig) for prophylaxis in haemophilia A with or without inhibitors. They review the study design, efficacy and safety results, and consider where Mim8 may fit into the rapidly evolving haemophilia treatment landscape. They also explore the key unanswered question: does Mim8 offer any meaningful clinical advantage over emicizumab, or is its main benefit greater convenience through fixed-volume administration?<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>

Episode thumbnail for Using AI to identify hospital acquired thrombosis

May 26, 2026

Using AI to identify hospital acquired thrombosis

<p>On this episode, Pip and Rich chat to Consultant Haematologist, Dr Kate Musgrave and Thrombosis Nurse Specialist, Vicky Marr about how they developed and implemented a natural language processing model that identifies cases of hospital acquired thrombosis. Implementing this strategy in their hospital in Newcastle-Upon-Tyne has led to saving thousands of hours of manually trawling radiology reports - enabling them to focus on what matters - interacting with patients. The tool is now available for implementation across the NHS. This is a must-listen for anyone wanting to improve efficiency in their hospital.</p><br><p><a href="https://www.newcastle-hospitals.nhs.uk/news/newcastle-hospitals-using-artificial-intelligence-ai-to-identify-preventable-blood-clots/" rel="noopener noreferrer" target="_blank">Read more about the project here.</a></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>

Episode thumbnail for Apixaban vs rivaroxaban: the trial we've all been waiting for

March 17, 2026

Apixaban vs rivaroxaban: the trial we've all been waiting for

On this episode, Pip and Rich discuss the <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2510703" rel="noopener noreferrer" target="_blank">COBRRA trial: Castellucci et al. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. NEJM. 2026.</a> The trial showed a convincing reduction in clinically relevant bleeding in patients treated with apixaban (3.3% vs 7.1%) and no difference in efficacy. It's a compelling study but there were important exclusion criteria and as ever, there are some nuances beyond the abstract. This episode also includes an update on Pip's daughter's school science project where unwitting families were invited for dinner to find out whether there is, indeed, always time for pudding.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>

35 total episodes available

Recent guests on Don't Just Read the Abstract

Guests from recent episodes — sign up to see every guest that has ever appeared on this show.

Dr Megan Kell

Guest

Dr Susie Shapiro

Guest

Deep-dive analytics for Don't Just Read the Abstract

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is Don't Just Read the Abstract?
<p>Want to stay up-to-date on the very latest developments in non-malignant haematology? Don't have the time or skills to critically appraise important papers? Join Pip and Rich, two haematology doctors on a journey of learning and discovery. Each episode, they will discuss a seminal trial, critically appraise the paper, interview a study author, and discuss the implications of the trial on clinical practice with a subject expert. CPD credits are available from RCPath. The podcast is sponsored by Sobi as a hands-off educational grant. Sobi have no editorial input whatsoever.</p><br><p>This podcast helps you to go beyond the abstract, delving deep into the methods, results, subanalyses, and implications. Interviews with authors gives a real-life perspective on the running of a clinical trial allowing explanations of why they did what they did and good honest discussion on limitations and how they might do it differently next time.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
How often does this podcast release new episodes?

This podcast updates bi-weekly.

Where can I listen to this podcast?

This podcast is available on 7 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

Yes, this podcast regularly features guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.